COLON ERDERLY LOW DOSE

Recruiting now

Conditions studied: Colon Adenocarcinoma

In brief

In this retrospective observational study, the case series of patients undergoing first-line treatment for metastatic colorectal adenocarcinoma with doublet fixed-dose and reduced-dose chemotherapy in combination with full-dose monoclonal antibody in patients aged 70 years or older is collected.

Key facts

Study ID

NCT06840977

Run by

Matteo Clavarezza

People needed

51

Starts

2026-07-07

Expected to finish

2027-07-31

Last updated by the study team

2026-07-16

Who can join

Age: 70 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with metastatic colorectal adenocarcinoma not treated with any therapy in the metastatic phase. Previous (neo)-adjuvant treatment with fluoroderivatives with or without Oxaliplatin is permitted.
• Age ≥ 70 years
• G8 score ≥ 12
• Patients with colorectal adenocarcinoma MSS
• Patients with BRAF WT colorectal adenocarcinoma
• Ability to understand and sign the informed consent form.

You may not qualify if…

• Patients with MSI tumours
• Patients with BRAF V600E mutated tumours
• Patients not eligible for doublet chemotherapy by clinical decision

Where it is running

• E.O. Ospedali Galliera — Genova, GE, Italy (enrolling)
• E.O. Ospedali Galliera — Genoa, Liguria, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.